Full history for every metric is available with a Kvantra account
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR m | 0 | 2,435 | 1,912 | 2,123 | 1,506 | 750 | 594 | 594 |
| Operating profit | INR m | 61 | 61 | ||||||
| Net profit | INR m | -0 | 18 | 66 | 13 | 10 | -202 | 11 | 11 |
| EPS reported | INR | 1.00 | 0.85 | ||||||
| Operating cashflow per share | INR | -15.14 | 0.05 | ||||||
| Capex per share | INR | 1.08 | 0.00 | ||||||
| FCF per share | INR | -16.21 | 0.05 | ||||||
| Free cash flow | INR m | -180 | 1 | ||||||
| Net debt | INR m | 283 | 283 | ||||||
| Book value equity | INR m | 456 | 456 | ||||||
| Book value per share | INR | 41.05 | 27.04 | ||||||
| Number of shares | m | 11.11 | 16.86 | ||||||
| DPS (TTM paid) | INR | 0.00 | 0.00 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 28.98 | 42.85 | ||||||
| P/B LTM | x | 0.71 | 0.76 | ||||||
| P/S LTM | x | 0.54 | 0.58 | ||||||
| P/FCF LTM | x | -1.79 | 447.70 | ||||||
| EV/EBITDA LTM | x | 7.14 | 7.34 | ||||||
| EV/Sales LTM | x | 1.02 | 1.06 | ||||||
| Earnings Yield LTM | % | 3.45% | 2.33% | ||||||
| FCF Yield | % | -55.79% | 0.22% | ||||||
| Quality | |||||||||
| ROE | % | 2.44% | 5.06% | ||||||
| ROIC | % | 5.67% | 5.67% | ||||||
| Operating margin | % | 10.21% | 10.21% | ||||||
| Gross margin | % | 24.04% | 26.88% | ||||||
| FCF/Sales | % | -30.32% | 0.13% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -20.79% | -20.79% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.40 | 0.00 | ||||||
| Net Debt/EBITDA | x | 3.33 | 3.30 | ||||||
| EBIT/Net interest | x | 1.24 | 1.24 | ||||||
| Net debt/market cap | % | 87.52% | 81.84% | ||||||
| Net debt/Equity | x | 0.62 | 0.62 | ||||||
| Gross debt/equity | x | 0.99 | 0.99 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 2016 and based in Hyderabad, India, Vineet Laboratories Limited specializes in the exploration, development, production, and marketing of active pharmaceutical ingredients (APIs) and specialty chemicals across India. The company's product offerings encompass key intermediates for various APIs, such as lopinavir, ritonavir, efavirenz, nadolol, glimepiride, celecoxib, and olanine, alongside a selection of other API precursors. Furthermore, they provide a diverse array of fine chemicals and laboratory reagents, including, but not limited to, isopropyl-beta-d-thiogalactopyranoside, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Vineet Laboratories Limited (VINEETLAB.BO)
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 2016 and based in Hyderabad, India, Vineet Laboratories Limited specializes in the exploration, development, production, and marketing of active pharmaceutical ingredients (APIs) and specialty chemicals across India. The company's product offerings encompass key intermediates for various APIs, such as lopinavir, ritonavir, efavirenz, nadolol, glimepiride, celecoxib, and olanine, alongside a selection of other API precursors. Furthermore, they provide a diverse array of fine chemicals and laboratory reagents, including, but not limited to, isopropyl-beta-d-thiogalactopyranoside, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free